Loading stock…

Intellia Therapeutics, Inc. (NTLA) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Intellia Therapeutics, Inc.

NTLAMarket cap $1.77BPrice $12.6

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops CRISPR-based gene editing therapies designed to cure genetic diseases with a single treatment. Its NTLA-2001 was the first-ever in-body CRISPR therapy to show clinical proof that editing genes directly inside patients actually works.

In Bastion Portfolios?

52W Return-49%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+9%6

Revenue Forecast

Rev CAGR (1y)-26%1

Rev CAGR (3y)+44%10

Rev CAGR (5y)+70%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-712%1

Net Income Margin-672%1

Free Cash Flow Margin-586%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-55%1

ROA-46%1

Earnings Stabilityna–

GEAR+VERY WEAK4

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV2.46

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-19.7%1

Dividend Yieldna–

Momentum

Short term

1 month return+3%9

3 month return-18%2

YTD return+40%9

Mid term

Price vs 52wHigh45%1

1 year return-51%1

Long term

3 year return-58%1

5 year return-90%1

Risk Shield

Price Risk

Beta2.01

Volatility98%1

Free Cash Flow

Free Cash Flow Margin-586%1

Free Cash Flow Yield-19.7%1

Quality

ROCE-54%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

NTLAIntellia Therapeutics

Revenue FY25$68M

GROWTH RATING↗

AVERAGE67 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+9%6

Revenue, next 1Y-26%1

Revenue, next 3Y, CAGR+44%10

Revenue, next 5Y, CAGR+70%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 67% of companies worldwide.

Revenue is set to grow 44%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 9%/yr over the last 3 years and is set to grow 44%/yr from here.

The runway holds up: revenue is set to grow 70%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK7 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+3%9

3-month return-18%2

YTD return+40%9

MID & LONG-TERM▾SCORE

% of 52-week high45%1

1-year return-51%1

3-year return-58%1

5-year return-90%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+3%) and so far this year (+40%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-58% over three years and -90% over five), behind 90% of the market.

It's down 51% over the past year, now 55% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-18%).

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Intellia Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

NTLAIntellia Therapeutics

Revenue FY25$68M

GROWTH RATING↗

AVERAGE67 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+9%6

Revenue, next 1Y-26%1

Revenue, next 3Y, CAGR+44%10

Revenue, next 5Y, CAGR+70%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 67% of companies worldwide.

Revenue is set to grow 44%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 9%/yr over the last 3 years and is set to grow 44%/yr from here.

The runway holds up: revenue is set to grow 70%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK7 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+3%9

3-month return-18%2

YTD return+40%9

MID & LONG-TERM▾SCORE

% of 52-week high45%1

1-year return-51%1

3-year return-58%1

5-year return-90%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+3%) and so far this year (+40%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-58% over three years and -90% over five), behind 90% of the market.

It's down 51% over the past year, now 55% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-18%).

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Intellia Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community